Trade Articles
Outsourcing Pharma | November 2024
Overcoming nonspecific binding challenges in pharmacokinetic assays
Drug, Discovery & Development | August 2024
Key toxicology considerations for large molecule therapies
American Pharmaceutical Review | August 2024
Tailored Treatment: Biomarkers and the Path to Precision Medicine Based on a ‘Fit-for Purpose’ Strategy
American Pharmaceutical Review | July 2024
Optimizing ADC Bioassays: LC-MS/MS Blends Speed with Cost-Effectiveness
Contract Pharma | June 2024
Exploring Oligonucleotide Drugs: An Overview of Pharmacokinetic & Bioanalytical Strategies
Drug Discovery and Development | May 2024
Beyond chemotherapy: The rise of precision medicine with radionuclide drug conjugates
Pharmaceutical Outsourcing | February 2024
How a New Rapid EMSA Method is Impacting Plasma Protein Binding in Oligonucleotides
Drug Discovery and Development | December 2023
Integrated bioanalysis strategies in nonclinical early in-vivo PK studies of siRNAs
Drug Discovery and Development | November 2023
Anticipating IND submission: Ensuring your drug is ready for preclinical toxicology studies
Outsourcing Pharma | September 2023
A deep dive with WuXi AppTec into HPAPIs: Risks, regulations, and revolutionary applications
Medical Design Sourcing | July 2023
Bridging bioanalytical gaps: Examining validation methods across species
Drug Discovery and Development | April 2023
Development challenges and regulatory changes for cell and gene therapies
ONdrugDelivery | March 2023
Overcoming challenges when developing oligonnucleotides for opthalmic drugs
Drug Discovery and Development | February 2023
Overcoming the challenges of metabolite identification and profiling for developing oligonucleotides
Drug Discovery and Development | November 2022
How MetID studies can improve safety and efficacy in PROTAC drugs
GEN News | November 2022
Bioanalysis Considerations for CAR T-Cell Therapies
Contract Pharma | October 2022
Comprehensive Bioanalysis of ADCs in DMPK Studies
OnDrug Delivery | August 2022
Dissecting the Delicate Delivery Process for Ocular Gene Therapy
American Pharmaceutical Review | August 2022
Antibody-Drug Conjugates (ADCs): Potent Cancer Killers with PK Challenges
Bioanalysis Zone | June 2022
Utilizing Monoclonal Antibodies to Regulate Checkpoint Proteins & Boost Immune Response
Drug Discovery & Development | February 2022
5 questions drug developers need to ask when vetting laboratory testing partners
Pharmaceutical Outsourcing | May 2022
Protein Biomarkers: The Correlation Between Proteins, Health Conditions and Exogenous Products
Contract Pharma | June 2022
Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
American Pharmaceutical Review | December 2021
Improving Preclinical Outcomes: De-Risking Your Drug Development Program
Contract Pharma | June 2021
Preparing for Preclinical Testing: A Readiness Checklist
Life Science Leader | May 2021
Improving Submission Quality: Preparing For Regulatory Differences
Pharma Manufacturing | July 2024
What USP <665> means for the future of pharma manufacturing
OutsourcingPharma | June 2024
Examining the Impact of Personalized Medicine on Reproductive Health
MedTech Intelligence | April 2024
From Concept to Market: The Strategic Journey from IND to NDA
American Pharmaceutical Review | February 2024
Embracing the Future: How In Vitro Assays Are Transforming Nonclinical Toxicology
Contract Pharma | January 2024
Stability Testing for Drug Products: Ensuring Safety, Efficacy & Regulatory Compliance
Drug Discovery and Development | November 2023
Unlocking the secrets of cellular immunogenicity: A deep dive in ELISpot assays
Drug Discovery and Development | September 2023
Exploring future cancer therapies: Designing linkers to increase ADC efficacy and reduce toxicity
Pharmaceutical Outsourcing | August 2023
The Role and Challenges of Plasma Protein Binding in Oligonucleotide Drug Development
Drug Discovery and Development | July 2023
Bridging bioanalytical gaps: Examining validation methods across species
Pharma Manufacturing | March 2023
Streamlining HPAPI development: How to manage highly potent APIs through a preclinical testing process
ONdrugDelivery | February 2023
Extractables/Leachables Testing Considerations For Single-Use Systems
Drug Metabolism and Disposition | January 2023
Detection and characterization of in vitro payload-containing catabolites of non-cleavable ADCs by high-resolution mass spectrometry and multiple data-mining tools
Bioanalysis Zone | November 2022
Bioanalytical considerations for gene and cell therapeutic products
Drug Discovery and Development | October 2022
Preparing an IND submission: Here is what drug sponsors should anticipate
Bioanalysis Zone | August 2022
Examining the dominant bioanalytical methods for Oligo development
OnDrug Delivery | March 2022
Drug Discovery & Development | July 2022
Bioanalytical method development and validation using Quanterix’s Simoa platform
Drug Discovery & Development | December 2021
The opportunities and challenges inherent in using protein biomarkers for new drug development
Genetic Engineering and Biotechnology News | November 2021
Using In Vitro–In Vivo Extrapolation to Predict Human Clearance
Drug Discovery & Development | May 2021
Managing critical reagents through drug development
Drug Discovery & Development | April 2021
Analyzing FDA guidance on DDI studies for therapeutic proteins
PharmaManufacturing | March 2021
Winning the drug development relay
Regulatory Focus | June 2021
The transition to ICH M10 and its impact on global submissions
AAPS Journal | May 2021
Bioanalysis in the Age of New Drug Modalities